Zydus Lifesciences bags FDA approval for Lacosamide Tablets in seizures
Zydus Lifesciences Limited, a prominent player in the pharmaceutical industry, has recently received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Lacosamide Tablets USP. These tablets, available in strengths of 50 mg, 100 mg, 150 mg, and 200 mg, are primarily indicated for the treatment of partial-onset seizures […]